New Treatment on the Horizon | PARP inhibitor - olaparib

We’re delighted that research has led to a new potential treatment option for people with breast cancer caused by changes in BRCA genes. New research has shown that one year of a PARP inhibitor called olaparib can reduce the risk of recurrence and progression to secondary breast cancer in people with early breast cancer, who have an altered BRCA gene.

These results are the culmination of over a decade of work, which our researchers were involved with from the very beginning. New knowledge like this gives us real hope for the future. We can’t wait to see what breakthroughs could be next.  

--

We’re Breast Cancer Now, the charity that’s steered by world-class research and powered by life-changing care. We’re here for anyone affected by breast cancer, the whole way through, providing support for today and hope for the future.

We’re that trusted friend that you turn to for caring support and help when you need it most. That expert authority on breast cancer research who is making breakthroughs and driving forward progress. And that vehicle for change, acting now to make sure anyone affected by breast cancer gets the best possible treatment and care.

We believe that we can change the future of breast cancer and make sure that, by 2050, everyone diagnosed with the disease lives – and is supported to live well. But we need to act now. Find out more:

#BreastCancer #BreastCancerResearch #Cancer #Charity